GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Surgery Partners Inc (NAS:SGRY) » Definitions » EV-to-EBITDA

SGRY (Surgery Partners) EV-to-EBITDA : 14.68 (As of Oct. 31, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Surgery Partners EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Surgery Partners's enterprise value is $6,949 Mil. Surgery Partners's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 was $473 Mil. Therefore, Surgery Partners's EV-to-EBITDA for today is 14.68.

The historical rank and industry rank for Surgery Partners's EV-to-EBITDA or its related term are showing as below:

SGRY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 11.27   Med: 20.76   Max: 45.89
Current: 14.68

During the past 12 years, the highest EV-to-EBITDA of Surgery Partners was 45.89. The lowest was 11.27. And the median was 20.76.

SGRY's EV-to-EBITDA is ranked worse than
56.25% of 480 companies
in the Healthcare Providers & Services industry
Industry Median: 12.52 vs SGRY: 14.68

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-10-31), Surgery Partners's stock price is $28.80. Surgery Partners's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was $-0.270. Therefore, Surgery Partners's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Surgery Partners EV-to-EBITDA Historical Data

The historical data trend for Surgery Partners's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Surgery Partners EV-to-EBITDA Chart

Surgery Partners Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.09 21.06 22.16 16.18 18.58

Surgery Partners Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.52 17.73 18.58 17.15 16.70

Competitive Comparison of Surgery Partners's EV-to-EBITDA

For the Medical Care Facilities subindustry, Surgery Partners's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Surgery Partners's EV-to-EBITDA Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Surgery Partners's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Surgery Partners's EV-to-EBITDA falls into.



Surgery Partners EV-to-EBITDA Calculation

Surgery Partners's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=6949.130/473.3
=14.68

Surgery Partners's current Enterprise Value is $6,949 Mil.
Surgery Partners's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $473 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Surgery Partners  (NAS:SGRY) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Surgery Partners's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=28.80/-0.270
=At Loss

Surgery Partners's share price for today is $28.80.
Surgery Partners's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.270.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Surgery Partners EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Surgery Partners's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Surgery Partners Business Description

Traded in Other Exchanges
Address
340 Seven Springs Way, Suite 600, Brentwood, TN, USA, 37027
Surgery Partners Inc is a healthcare services company with an integrated outpatient delivery model focused on providing quality, cost-effective solutions for surgical and related ancillary care in support of both patients and physicians. It operates in two segments: Surgical Facility Services and Ancillary Services out of which the Surgical Facility Services segment accounts for the majority of revenue.
Executives
Harrison R. Bane officer: American Group President 310 SEVEN SPRINGS WAY, SUITE 500, BRENTWOOD TN 37027
Danielle Burkhalter officer: Chief Human Resources Officer 310 SEVEN SPRINGS WAY, SUITE 500, BRENTWOOD TN 37027
Bradley R. Owens officer: National Group President 310 SEVEN SPRINGS WAY, SUITE 500, BRENTWOOD TN 37027
David T Doherty officer: Chief Financial Officer 310 SEVEN SPRINGS WAY, BRENTWOOD TN 37027
Jason Eric Evans officer: EVP & Chief Operating Officer 310 SEVEN SPRINGS WAY, SUITE 500, BRENTWOOD TN 37027
Anthony Taparo officer: President, Atlantic Group 310 SEVEN SPRINGS WAY, SUITE 500, BRENTWOOD TN 37027
Jennifer Baldock officer: Sr. VP, Gen Couns. & Sec. 310 SEVEN SPRINGS WAY, SUITE 500, BRENTWOOD TN 37027
Marissa Brittenham officer: Chief Strategy Officer 310 SEVEN SPRINGS WAY, BRENTWOOD TN 37027
Bain Capital Investors Llc director, 10 percent owner 200 CLARENDON STREET, BOSTON MA 02116
T. Devin O'reilly director, 10 percent owner C/O BAIN CAPITAL PRIVATE EQUITY, LP, 200 CLARENDON STREET, BOSTON MA 02149
Blair E Hendrix director, 10 percent owner
Andrew T. Kaplan director C/O BAIN CAPITAL PRIVATE EQUITY, LP, 200 CLARENDON STREET, BOSTON MA 02116
Wayne S Deveydt director, officer: Chief Executive Officer 120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204
Bain Capital Partners Xi, L.p. director, 10 percent owner 200 CLARENDON STREET, BOSTON MA 02116
Bain Capital Fund Xi, L.p. director, 10 percent owner JOHN HANCOCK TOWER, 200 CLARENDON STREET, BOSTON MA 02116